24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
Launched by FREEDOM LASER THERAPY, INC. · Sep 12, 2012
Trial Information
Current as of April 26, 2025
Unknown status
Keywords
ClinConnect Summary
The test treatment is the iRestore™ Hair Rejuvenation System. The device irradiates the scalp with visible light using 5 mW (class 3a) lasers. It is to be used approximately 3 times per week for approximately 30 minutes at each session.
The System is placed on the head and adjusted to a comfortable size by rotating knobs on the side of the device. If needed, subjects may replace the soft pad on the inside of the device with the thinner pad provided. There will be 2 options for using the product. The subject will either insert the 5-V AC power adapter pin into the device remote control, and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Individuals eligible for inclusion in the study are those who:
- • 1. Are male or female, 25 to 60 years of age;
- • 2. If male, have Norwood-Hamilton classifications of IIa to V male pattern baldness;
- • 3. If female, have Ludwig Scale classifications I-4, II-1, II-2, or frontal;
- • 4. Are willing to have a tattoo created on the target area;
- • 5. Have been experiencing active hair loss within the last 12 months;
- • 6. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence or partner's vasectomy: abstinence or partner's vasectomy are acceptable if the female agrees to implement one of the other acceptable methods of birth control if her lifestyle or partner changes);
- • 7. Have Fitzpatrick Skin Type I-IV (See Table 1 Below);
- • 8. Are willing to have the target area hair clipped;
- • 9. Read, understand, and sign a photographic release form(s); and
- • 10. Read, understand, and sign an informed consent document after being advised of the nature of the study.
- • Table 1: Fitzpatrick Skin Types I Always burns easily, never tans II Always burns easily, tans minimally III Burns moderately, tans gradually (light brown) IV Burns minimally, always tans well (moderate brown) V Rarely burns, tans very well (moderate brown) VI Never burn, deeply pigmented
- Exclusion Criteria:
- * Individuals excluded from participation in the study are those who:
- 1. Have used any of the following medications within 6 months prior to enrollment:
- • minoxidil, finasteride (or any other 5α-reductase inhibitor medications);
- • medications with anti-androgenic properties (eg, cyproterone, spironolactone, ketoconazole, flutamide, and bicalutamide);
- • topical estrogens, progesterone, tamoxifen, anabolic steroids;
- • medications that can potentially cause hypertrichosis (eg, ciclosporin, diazoxide, phenytoin, and psoralens);
- • oral glucocorticoids (inhaled glucocorticoids are permitted);
- • lithium or phenothiazines;
- • medications of known or suspected phototoxicity (eg, tetracyclines, thiazides, certain NSAIDs);
- • other medications which, in the opinion of the investigator, may interfere with the performance of study assessments or place the subject at undue risk;
- • 2. Will not agree to refrain from changing hair color and hair style during the course of the study;
- • 3. Have had a hair transplant, scalp reduction, hair weave, or tattoo which, in the opinion of the investigator, may interfere with the performance of the study assessments;
- • 4. Are using or have used depilatories, razors, or wax on the scalp to an extent which, in the opinion of the investigator, may interfere with the performance of the study assessments;
- • 5. Have psoriasis, active dermatitis/eczema, or severe acne on the scalp area;
- • 6. Have diabetes requiring exogenous insulin;
- • 7. Have cataracts;
- • 8. Have any medical condition which, in the opinion of the investigator, could affect hair growth (eg, Human Immunodeficiency Virus, connective tissue disease, inflammatory bowel disease);
- • 9. Have very little contrast between hair color and scalp, eg, are of a fair hair color (eg, white or very blond) and have very pale skin;
- • 10. Are females who are pregnant, planning to become pregnant during the study, or breastfeeding; and/or
- • 11. Are, in the opinion of the investigative personnel, unable to comprehend and/or otherwise comply with any aspect of study requirements.
About Freedom Laser Therapy, Inc.
Freedom Laser Therapy, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative treatments in the field of pain management and rehabilitation. With a focus on non-invasive laser therapy technologies, the company aims to enhance patient outcomes through rigorous research and development. Freedom Laser Therapy, Inc. collaborates with healthcare professionals and research institutions to conduct clinical trials that explore the efficacy and safety of its cutting-edge therapeutic modalities. Committed to evidence-based practices, the company strives to improve the quality of life for patients while contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paramus, New Jersey, United States
Patients applied
Trial Officials
Jonathan Dosik, MD
Principal Investigator
TKL Research, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials